INNERGY

INNERGY LOROBLIS 16 ORODISPERSIBLE TABLETS

You're reading an Auto-translation.

Mechanism of action

Although it is a commensal bacterial strain, Streptococcus salivarius K12 produces 2 bacteriocins: the antimicrobial peptides Salivaricin A2 and Salivaricin B, which have the potential to inhibit the development of pathogenic bacterial strains responsible for bacterial pharyngitis and tonsillitis, acute otitis media, and halitosis (e.g., Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis).

In addition to its potential to maintain and restore eubiosis in the oral cavity and pharynx, Streptococcus salivarius K12 has antiviral activity, anti-inflammatory activity, and antifungal properties, supported by in vitro and in vivo studies.

Recommendation

Clinical studies have shown that Loroblis contributes to the maintenance and development of a protective microbial flora in the oral cavity and pharynx, with potential in:

• Prophylaxis of upper respiratory tract infections (pharyngitis, tonsillitis, otitis media);
• Treatment of mild and moderate upper respiratory tract infections;
• Treatment of oral inflammatory conditions (stomatitis, gingivitis, candidiasis, halitosis);
• Supportive therapy after antibiotic treatment of upper respiratory tract infections.

Method of administration

Loroblis is recommended for adults and children over 3 years of age: 1 orodispersible tablet/day, dissolved slowly in the oral cavity, in the evening after oral hygiene, according to your doctor's recommendation, up to 1 orodispersible tablet/day, for 90 days for the prophylaxis of recurrent upper respiratory tract infections (recurrent pharyngitis, tonsillitis, otitis media).

It is unnecessary to administer Loroblis concomitantly with antibiotics, due to the strong sensitivity of the Streptococcus salivarius K12 strain to antibiotics;

Precautions

Immunocompromised individuals, those undergoing certain treatments (chemotherapy, radiotherapy), or those with severe leukopenia should consult a doctor before administering the product.

Composition

One Loroblis orodispersible tablet contains (minimum) 1x109 CFU Streptococcus salivarius K12 (BLIS K12).

Streptococcus salivarius K12 is a bacterial strain that colonizes the oral cavity and nasopharynx of healthy individuals and is part of the normal bacterial flora.